2-((3-bromopyridin-2-yl)oxy)ethanol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-((3-bromopyridin-2-yl)oxy)ethanol
• 英文别名: 2-[(3-Bromopyridin-2-yl)oxy]ethanol；2-(3-bromopyridin-2-yl)oxyethanol
• 化学式: C₇H₈BrNO₂
• 分子量: 218.05
• InChiKey: OYHCSVAQQLLOLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  42.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-((3-bromopyridin-2-yl)oxy)ethanol 、 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine 生成 2-({3-[4-(2-aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}oxy)ethanol
  参考文献：
  名称：

  FLAP MODULATORS

  摘要：

  本发明涉及公式(I)的化合物，或其形式，其中环A、R1、R2、R3、R3'、L、W和V的定义如本文所述，可用作FLAP调节剂。本发明还涉及包含公式(I)化合物的制药组合物。制备和使用公式(I)化合物的方法也属于本发明的范围。

  公开号：

  US20150259357A1
• 作为产物：
  描述：

  3-溴-2-氯吡啶 、 乙二醇 在 sodium hydride 作用下， 以 mineral oil 为溶剂， 生成 2-((3-bromopyridin-2-yl)oxy)ethanol
  参考文献：
  名称：

  FLAP MODULATORS

  摘要：

  本发明涉及式（I）的化合物，或其形式，其中环A，R1，R2，R3，R3'，L，W和V如本文所定义，可用作FLAP调节剂。该发明还涉及包含式（I）化合物的药物组合物。制备和使用式（I）化合物的方法也属于本发明的范围。

  公开号：

  US20150259357A1

文献信息

• Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same
  申请人：Hoveyda Hamid R.

  公开号：US20110105389A1

  公开（公告）日：2011-05-05

  The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (GRLN, growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and/or variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as antagonists or inverse agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, obesity and obesity-associated disorders, appetite or eating disorders, addictive disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hyperproliferative disorders, central nervous system disorders and inflammatory disorders.

  本发明提供了新型构象定义的大环化合物，已被证明是生长激素分泌素受体（GRLN，生长激素分泌素受体，GHS-R1a及其亚型、异构体和/或变种）的选择性调节剂。本文还描述了合成这些新型化合物的方法。这些化合物可用作生长激素分泌素受体的拮抗剂或逆向激动剂，以及用于治疗和预防一系列医学疾病，包括但不限于代谢和/或内分泌紊乱、肥胖和与肥胖相关的疾病、食欲或进食紊乱、成瘾紊乱、心血管疾病、胃肠道疾病、遗传疾病、过度增殖性疾病、中枢神经系统疾病和炎症性疾病。
• Macrocyclic Modulators of the Ghrelin Receptor
  申请人：Marsault Eric

  公开号：US20090221689A1

  公开（公告）日：2009-09-03

  The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

  本发明提供了新型构象定义的大环化合物，已被证明是生长激素释放肽受体（GHS-R1a及其亚型，同工型和变异体）的选择性调节剂。本文还描述了合成新型化合物的方法。这些化合物可用作生长激素释放肽受体的激动剂，并作为治疗和预防一系列医疗状况的药物，包括但不限于代谢和/或内分泌紊乱，胃肠道疾病，心血管疾病，肥胖和肥胖相关疾病，中枢神经系统疾病，遗传性疾病，高增殖性疾病和炎症性疾病。
• METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR
  申请人：Fraser Graeme L.

  公开号：US20110288163A1

  公开（公告）日：2011-11-24

  The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
• AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS
  申请人：RaQualia Pharma Inc.

  公开号：US20170002016A1

  公开（公告）日：2017-01-05

  The present invention relates to azaspiro derivatives of the formula (I) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the TRPM8 receptor.
• US9079866B2
  申请人：——

  公开号：US9079866B2

  公开（公告）日：2015-07-14